Peptide record

TPDB92089

NK-2 Antibacterial Anticancer Antifungal Antiparasitic Toxicity modified_plain modified
27 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92089
NK-2
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP dbAMP 3.0 iACP-DRLF CAFPdb i2APP
modified_plain
Yes
A 27-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KILRGVCKKIMRTFLRRISKDILTGKK-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
27 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antibacterial Antimicrobial Anticancer Activity
NK-lysin Synthetic peptide Residue of 39-65 of porcine NK-lysine Activity
Evidence Records 13 records
Evidence 1 Activity

Activity

LD50
LD50=1-4 µM
Anticancer
1-4 µM

Target

Colorectal Cancer
NB LA-N-1
Colon

Assay & Model

PI-uptake assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

LD50
LD50=1-4 µM
Anticancer
1-4 µM

Target

Brain Tumor
SH-SY5Y
Brain

Assay & Model

PI-uptake assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 3 Activity

Activity

LD50
LD50=30 µM
Anticancer
30 µM

Target

Lymphoma Cancer
U-937
Blood

Assay & Model

PI-uptake assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 4 Activity

Activity

LD50
LD50=1-4 µM
Anticancer
1-4 µM

Target

Leukemia Cancer
SW-480
Blood

Assay & Model

PI-uptake assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 5 Activity

Activity

IC50
IC50 = ~70 µM
Anticancer
~70 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 6 Activity

Activity

IC50
IC50 = ~50 µM
Anticancer
~50 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 7 Activity

Activity

IC50
IC50 = ~50 µM
Anticancer
~50 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 8 Activity

Activity

IC50
IC50 = ~40 µM
Anticancer
~40 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 9 Activity

Activity

IC50
IC50= 4.3±0.3 µM
Anticancer
4.3

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 10 Activity

Activity

IC50
IC50= 70 µM (approx)
Anticancer
70 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 11 Activity

Activity

IC50
IC50= 50 µM (approx)
Anticancer
50 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 12 Activity

Activity

IC50
IC50= 50 µM (approx)
Anticancer
50 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 13 Activity

Activity

IC50
IC50= 40 µM (approx)
Anticancer
40 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013